Methyltestosterone Dosage

Medically reviewed by Drugs.com. Last updated on Aug 4, 2023.

Applies to the following strengths: 10 mg; 25 mg

Usual Adult Dose for Hypogonadism - Male

10 to 50 mg orally once a day

Adjust dose based on patient's response and appearance of adverse reactions

Comments:

Prior to initiating, confirm hypogonadism diagnosis by ensuring serum testosterone concentrations have been measured in the morning on at least 2 separate days and these serum testosterone concentrations are below the normal range.
Safety and efficacy in men with age-related hypogonadism (also referred to as late-onset hypogonadism) have not been established.

Uses: For replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone such as congenital or acquired primary hypogonadism or congenital or acquired hypogonadotropic hypogonadism.

Usual Adult Dose for Breast Cancer-Palliative

50 to 200 mg orally once a day

Comments:

Use of androgen therapy in women should be made by an oncologist with expertise in this field; androgen therapy occasionally appears to accelerate disease.
Some premenopausal women with hormone-responsive therapy have benefited from androgen therapy.

Use: Adjunctive therapy in women with advancing inoperable breast cancer who are 1 to 5 years postmenopausal.

Usual Pediatric Dose for Delayed Puberty - Male

10 to 50 mg orally once a day

Delayed Puberty:

Dosing generally starts at the lower end of the dosing range
Titrate according to patient response and tolerance
Duration of therapy should be limited to 4 to 6 months

Comments:

If androgen deficiency occurs prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics; prolonged androgen treatment will be required to maintain sexual characteristics.
Dosing should be adjusted based on patient's response and appearance of adverse reactions.

Uses:

For replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone such as congenital or acquired primary hypogonadism or congenital or acquired hypogonadotropic hypogonadism.
Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty

Usual Pediatric Dose for Hypogonadism - Male

10 to 50 mg orally once a day

Delayed Puberty:

Dosing generally starts at the lower end of the dosing range
Titrate according to patient response and tolerance
Duration of therapy should be limited to 4 to 6 months

Comments:

If androgen deficiency occurs prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics; prolonged androgen treatment will be required to maintain sexual characteristics.
Dosing should be adjusted based on patient's response and appearance of adverse reactions.

Uses:

For replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone such as congenital or acquired primary hypogonadism or congenital or acquired hypogonadotropic hypogonadism.
Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty

Renal Dose Adjustments

Use with caution

Liver Dose Adjustments

Use with caution

Precautions

CONTRAINDICATIONS:

Men with carcinomas of the breast or with known or suspected carcinomas of the prostate
Women who are or may become pregnant

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule III

Dialysis

Data not available

Other Comments

Administration advice:

Administer orally

Storage requirements:

Protect from light and moisture

General:

Androgen therapy should be used very cautiously in children and only by specialists aware of the effects on bone maturation.

Monitoring:

Periodic liver function tests should be performed
Prepubertal males should have X-ray examinations of bone age every 6 months
Periodically evaluate hemoglobin and hematocrit for polycythemia, especially with high doses
Women should have frequent determinations of urine and serum calcium levels

Patient advice:

Female patients should be instructed to report signs of virilization such as deepening voice, hirsutism, acne, clitoromegaly, and/or menstrual irregularities.
Male patients should be instructed to report too frequent or persistent penile erections.
All patients should be instructed to report signs and symptoms of jaundice or edema.
Patients should understand this drug has been associated with venous thromboembolic events; they should be instructed to contact their healthcare provider promptly if signs or symptoms of DVT or PE develop.
Patients should understand that this drug has been subject to abuse; steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions.